Thiazolidinedione derivative and its use as antidiabetic
CA 2370258 A1 · Owner: Sasse, Michael John · Inventors: Sasse, Michael John; Giles, Robert Gordon; Blackler, Paul David James
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A polymorphic form of 5-4-2-(N-methyl-N-(2pyridyl)amino)ethoxybenzylthiazolidine-2,4-dione maleic acid salt (the , "Polymorph") characterised in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and 669 cm-1; and/or (ii) provides a Raman spectrum containing peaks at 1581 768, 670, 271 and 226 cm-1; and/or , (iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peaks substantially as set out in Table II; a process for preparing such a compound a pharmaceutical composition containing such a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 19, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 19, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 19, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.